CAPRIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H20O2
Molecular Weight	172.2646
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCCCCCCCCC(O)=O

InChI

InChIKey=GHVNFZFCNZKVNT-UHFFFAOYSA-N

InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C10H20O2
Molecular Weight	172.2646
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Capric acid (decanoic acid) is a medium-chain fatty acid found in saturated fats (cow butter, and plant oils like coconut oil). Capric acid is a major constituent of the MCT ketogenic diet, providing about 40% of the medium chain fat within the diet. The acid is discussed to have positive effect on seizure control through direct AMPA receptor inhibition and on mitochondrial diseases through the binding to PPARgamma. It readily crosses the blood-brain barrier, probably by a combination of diffusion and saturable carrier-mediated transport via a medium-chain fatty acid transporter.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate receptor ionotropic AMPA 41	Antagonist 2,778		0.43 mM [IC50]
Peroxisome proliferator-activated receptor gamma 111	Modulator 828		41.7 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Inherited metabolic diseases 2	Primary		Basic research	Unknown
Seizure 4	Primary		Preclinical	Unknown

PubMed

Show entries

Title	Date	PubMed
[New data on composition of esssential oil from inflorescence of everlasting (Helichrysum arenarium(L.) Moench.)].	2001 Aug	11862667
Outcome comparison of patients receiving oral or depot neuroleptic medication.	2001 Aug	11729538
Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers.	2001 Aug	11443038
Increased vigabatrin entry into the brain by polysorbate 80 and sodium caprate.	2001 Feb	11273010
Significance of substrate hydrophobicity for recognition by an oligopeptide transporter (PEPT1).	2001 Jul-Aug	11459451

Showing 1 to 5 of 30 entries

Previous1 2 3 4 5 6Next

Patents

Sample Use Guides

In Vivo Use Guide

The oral minimal dose is 1723 mg/kg (animal model).

Route of Administration: Oral

In Vitro Use Guide

In a seizure model, rat cortex-hippocampus slices were incubated with 100 uM and 1 mM of capric acid. The fatty acid was found to reduce the frequency of epileptiform discharges at these conentrations.